More M&A Deals Could Boost Biotech ETFs

December 12, 2012

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)


Head over to to learn more about ETFs within the biotech sector.


Lean why bond ETFs are an essential part of a diversified portfolio with our bond ETF channel.

Learn how currency-hedged ETFs can reduce the currency risk in your portfolio.


Investors took profits on U.S. equity ETFs on Friday, Nov. 20.

Top three issuers saw net inflows in their products on Monday, Nov. 23.


By Dave Nadig

With the SEC looking to regulate liquidity, should bond ETF investors worry?

By Matt Hougan’s conference offered several actionable ideas for investors.

By Dave Nadig

The exchange just proposed the latest rule to reinvent history on bad ETF trades.

By Matt Hougan

Best deal in the history of finance gets better.


By Nicholas Kalivas

The case for low-volatility, currency-hedged exposure in Europe.

By Nick Stonestreet

ETF firm builds out its business.

By Nicholas Kalivas

A sector-momentum strategy may be just what your portfolio needs in the current market environment.